Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

NCT03258047 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

B Cell Lymphoma

Interventions

COMBINATION_PRODUCT: CAR-T

Sponsor

First Affiliated Hospital of Zhejiang University